Immutep is listed on the Australian Stock Exchange (ASX:IMM) and on the NASDAQ Global Market (NASDAQ:IMMP) in the U.S. (ADR's).
We are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S.
We are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel.
Our objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. We have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.
Our lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), a first-in-class antigen presenting cell (APC) activator currently being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for breast cancer and melanoma.
Latest Media Releases
Latest News
Company Presentations /
by -
A month ago
11 Jun 2021 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Scientific and Medical Officer Dr Frédéric Triebel, and Director of Clinical Development and Re…
Market Reports /
by Melissa Darmawan -
3 months ago
08 Apr 2021 - The ASX continued its winning streak for the fifth day, gaining 1% to close at a 13-month high of 6,999. All sectors closed in the black. Miners performed strongly, w…
Market Reports /
by Melissa Darmawan -
3 months ago
08 Apr 2021 - The ASX exceeded 7000 points for the first time in 13 months in early trade. At noon, the S&P/ASX 200 index is 67 points up at 6,995. On the futures market, the SPI i…
Company News /
by Melissa Darmawan -
3 months ago
08 April 2021 - Biotechnology company Immutep (ASX:IMM) has received a fast-track approval from the United States Food and Drug Administration (FDA) for its lead product ‘efti’.
Interviews /
by Rachael Jones -
4 months ago
29 Mar 2021 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt talks about the Bristol Myers Squibb trial evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivo…
Interviews /
by Rachael Jones -
6 months ago
27 Jan 2021 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt analyses December's breast cancer data, and provides an update on efti's position and outlook.
Market Reports /
by Rachael Jones -
7 months ago
30 Dec 2020 - The ASX looks set to open lower this morning as Wall Street reversed their earlier gains. European stocks extended their end-of-year rally high in anticipation of fre…
Interviews /
by Rachael Jones -
8 months ago
03 Dec 2020 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt provides an update on the company, discussing a recent capital raise and results in lung cancer and he…
Company News /
by Rachael Jones -
8 months ago
19 Nov 2020 - Immutep Limited (ASX:IMM) is advancing clinical development for its lead product candidate eftilagimod alpha through the expansion of its ongoing TACTI-002 study and …
Interviews /
by Anna Napoli -
A year ago
24 Jun 2020 - Immutep (ASX:IMM) CEO, Marc Voigt provides an update on its clinical trials including metastatic breast cancer (MBC), its global leadership under Chief Scientist and …
Company Presentations /
by -
A year ago
09 Jun 2020 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Scientific and Medical Officer Dr Frédéric Triebel, and Director Clinical Development and Regul…
Market Reports /
by Rachael Jones -
A year ago
29 Apr 2020 - It has been a positive day of trade for the ASX the local bourse managed to close 1.5% higher. Shares in supermarket Coles (ASX:COL) are down despite growing supermar…
Company News /
by Rachael Jones -
A year ago
29 Apr 2020 - Biotech company Immutep (ASX:IMM) has today successfully completed a $12 million placement to professional, institutional and sophisticated investors.
Interviews /
by Katrina Bullock -
A year ago
11 Mar 2020 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's 1H20 results, including data from its clinical trials, collaborations with major pharma …
Company Presentations /
by -
A year ago
28 Feb 2020 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Scientific and Medical Officer, Dr Frédéric Triebel, and Director of Clinical Development and R…
Market Reports /
by Rachael Jones -
A year ago
09 Jan 2020 - Following positive leads from US markets, the ASX looks set to open higher this morning. On the commodities front, gold and oil fell as Middle East tensions eased. Ap…
Interviews /
by Rachael Jones -
A year ago
06 Nov 2019 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's clinical trial data for its Phase 1 trial in melanoma, TACTI-mel, where patients are res…
Interviews /
by Jessica Amir -
2 years ago
02 Jul 2019 - Immutep Limited (ASX:IMM) CEO & Executive Director, Marc Voigt, provides an update on the company's clinical trials, including its Phase IIb AIPAC study into metastat…
Company News /
by Rachael Jones -
2 years ago
06 Jun 2019 - Biotech company Immutep (ASX:IMM) reports that the first patient in the INSIGHT-004 Phase I clinical trial has received the first dose of treatment in Germany.
Market Reports /
by Katrina Bullock -
2 years ago
23 May 2019 - After opening flat the ASX200 lost momentum this morning. Despite a rally in the second half of the session, the ASX200 closed 0.3 per cent lower. This follows 6 sess…
Company News /
by Rachael Jones -
2 years ago
23 May 2019 - Biotech company Immutep (ASX:IMM), specialises in immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent by the…
Company News /
by Rachael Jones -
2 years ago
17 May 2019 - Biotech company Immutep (ASX:IMM) today announces more mature data relating to Part B of its ongoing phase I TACTImel clinical study of the Company’s lead product can…
Company Presentations /
by -
2 years ago
08 Apr 2019 - Immutep Limited (ASX:IMM) CEO, Marc Voigt, CSO & CMO, Professor Frederic Triebel and Director Clinical Development and Regulatory Affairs, Christian Mueller, provide …
Company Presentations /
by -
2 years ago
27 Mar 2019 - Immutep Limited (ASX:IMM) CEO, Marc Voigt, CSO & CMO, Dr Frederic Triebel discuss the latest clinical results and commercial options for funding development of IMP761…
Market Reports /
by Katrina Bullock -
2 years ago
22 Mar 2019 - After opening higher this morning following strong leads from Wall Street the ASX 200 saw an early rally, peaked just after midday and has been slowly easing off over…
